CMV DNA polymerase — Drug Target

All drugs that target CMV DNA polymerase — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Nucleoside analog antiviral

Marketed (1)

• prophylactic Valganciclovir · Rabin Medical Center · Nucleoside analog antiviral · Infectious Disease / Virology
  Valganciclovir is a prodrug of ganciclovir that inhibits viral DNA polymerase to prevent cytomegalovirus (CMV) replication in immunocompromised patients.

Phase 3 pipeline (2)

• Placebo to VGCV · Merck Sharp & Dohme LLC · Nucleoside analog antiviral · Infectious Disease / Virology
  VGCV (valganciclovir) is a prodrug of ganciclovir that inhibits viral DNA polymerase to suppress cytomegalovirus (CMV) replication.
• Valganciclovir CMV Prophylaxis · University of California, San Francisco · Nucleoside analog antiviral · Infectious Disease / Virology
  Valganciclovir is a prodrug that is converted to ganciclovir, which inhibits cytomegalovirus (CMV) DNA polymerase to prevent viral replication.